Sami Albattat

Sami Albattat

Auto-generated profile, based on publicly available information

Sami Albattat

Pediatric Department, Maternity and Children’s Hospital, Alhassa, Ministry of Health, Najran, Saudi Arabia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
SASami Albattat
Sami Albattat
AAAbbas Alabdultaif
Abbas Alabdultaif
FAFatimah Albattat
Fatimah Albattat
BABatla Albattat
Batla Albattat
Background: Emicizumab is a novel prophylactic medication used to treat patients with hemophilia A. It is indicated to minimize the frequency of bleeding episodes and the severity of serious bleeding in patients with hemophilia A utilizing inhibitors. However, some cases of bleeding episodes have been reported, and more data are needed regarding their management and expected outcomes. Case presentation: We report a case of a 4-year-old Saudi Arabian boy with severe hemophilia A who presented with a post-traumatic cerebral hemorrhage. The patient, with high titer inhibitors, was on emicizumab prophylaxis therapy. On hospital admission, he received tranexamic acid (10 mg intravenously, every 6 hours), and recombinant activated factor VII 120 µg/kg every 2 hours for 2 days then every 4 hours for 4 days. On follow-up, the patient showed no signs of neurological deficit. There was no need for emergency neurosurgical intervention since the bleeding had been controlled throughout the first 2 days. There were no recorded thrombotic sequelae or neurological complications, with complete resolution within 10 days. Conclusions: This case implies that low-dose recombinant activated factor VII might be used safely and effectively with patients with hemophilia A on emicizumab prophylaxis, to reduce the risk of cerebral hemorrhage or another episode of serious bleeding along with its long-term complications.

16 September 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
ATAhmad Tarawah
Ahmad Tarawah
SASami Albattat
Sami Albattat
ASAyman Shahba
Ayman Shahba
MNMohamed Nashat
Mohamed Nashat
SBSarah Brighton
Sarah Brighton
GMGeorge Morgan
George Morgan